Tissue Plasminogen Activator: Chemical and Physiological Aspects

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Seminars in Thrombosis and Hemostasis

• Publication date

  1984-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-2007-1004403PMID 6422555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis.

  2009cited by this paper
• Low fibrinolytic activity in the walls of veins in patients with thrombosis.

  2009cited by this paper
• The primary structure of human urogastrone.

  2009cited by this paper
• A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall.

  2009cited by this paper
• Serine proteases.

  1986cited by this paper
• Release of vascular plasminogen activator (v‐PA) after venous stasis: electrophoretic—zymographic analysis of free and complexed v‐PA

  1985cited by this paper
• Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.

  1984cited by this paper
• The mechanism of in vitro clot lysis induced by vascular plasminogen activator.

  1984cited by this paper
• Effects of hypoxia and acidosis on vascular plasminogen activator release in the pig ear perfusion system.

  1984cited by this paper
• Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.

  1983cited by this paper
• Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.

  1983cited by this paper
• Fibrinolytic activity in the walls of foot veins in women using combined contraceptive pills.

  1983cited by this paper
• Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo.

  1983cited by this paper
• Plasminogen activators in tissues of the immature and estrogen-stimulated rat uterus and in uterine luminal fluid: characterization and properties.

  1983cited by this paper
• Induction of plasminogen activator by 12-O-tetradecanoylphorbol-13-acetate and calcium ionophore. Suppression by inhibitors of fatty acid lipoxygenase.

  1983cited by this paper
• Isolation of cDNA sequences coding for a part of human tissue plasminogen activator.

  1983cited by this paper
• Plasminogen activator release during venous stasis and exercise as determined by a new specific assay.

  1983cited by this paper
• Production of human plasminogen activators by cell culture

  1983cited by this paper
• Structural characterization of tissue plasminogen activator purified by immunosorbent chromatopraphy

  1983cited by this paper
• Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one‐step affinity purification.

  1983cited by this paper
• Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

  1983cited by this paper
• Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2.

  1983cited by this paper
• Clot-selective coronary thrombolysis with tissue-type plasminogen activator.

  1983cited by this paper
• Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices.

  1983cited by this paper
• Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor.

  1983cited by this paper
• The primary structure of high molecular mass urokinase from human urine

  1982cited by this paper
• Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

  1982cited by this paper
• Interaction of Plasminogen Activators and Inhibitors with Plasminogen and Fibrin

  1982cited by this paper
• Prospective study of a phenformin-like substance (moroxydine chloride) in patients with deficient vessel wall fibrinolysis.

  1982cited by this paper
• A Comparison of Plasminogen Activators Derived from Rat Plasma, Primary Rat Hepatocytes and Isolated Perfused Rat Liver

  1982cited by this paper
• Turnover of Tissue Plasminogen Activator in Man

  1982cited by this paper
• Isolation of two variants of native one‐chain tissue plasminogen activator

  1982cited by this paper
• Cultured bovine endothelial cells produce both urokinase and tissue- type plasminogen activators

  1982cited by this paper
• Activation of protein C in vivo.

  1982cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin.

  1982cited by this paper
• Plasminogen activator production by trophoblast cells in vitro: effect of steroid hormones and protein synthesis inhibitors.

  1982cited by this paper
• Purification and characterization of human kidney plasminogen activator dissimilar to urokinase.

  1982cited by this paper
• Purification of Human Tissue-Type Plasminogen Activator in Centigram Quantities from Human Melanoma Cell Culture Fluid and Its Conditioning for Use In Vivo

  1982cited by this paper
• Structural relationship between human high and low molecular mass urokinase.

  1982cited by this paper
• Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase.

  1982cited by this paper
• The complete amino acid sequence of low molecular mass urokinase from human urine.

  1982cited by this paper
• A sensitive assay for tissue plasminogen activator.

  1982cited by this paper
• A proenzyme form of human urokinase.

  1982cited by this paper
• A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.

  1982cited by this paper
• Enzymatic properties of the one- and two-chain form of tissue plasminogen activator.

  1982cited by this paper
• Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.

  1982cited by this paper
• Messenger RNA for human tissue plasminogen activator.

  1982cited by this paper
• An Enhancing Effect of Poly-Lysine on the Activation of Plasminogen

  1982cited by this paper
• Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator.

  1982cited by this paper
• The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain.

  1982cited by this paper
• Studies on the kinetics of plasminogen activation by tissue plasminogen activator.

  1982cited by this paper
• The production of distinct forms of plasminogen activator by mouse embryonic cells.

  1982cited by this paper
• Plasminogen activator activity of superficial veins in acute deep venous thrombosis.

  1982cited by this paper
• Characteristics of Tissue Plasminogen Activator from Paranasal Mucous Membrane in Chronic Sinusitis

  1982cited by this paper
• Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators.

  1982cited by this paper
• New tissue sources and types of fibrinolytic enzymes.

  1982cited by this paper
• Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus

  1981cited by this paper
• Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator.

  1981cited by this paper
• Use of Chromogenic Substrate S-2251 for Determination of Plasminogen Activator in Rat Ovaries

  1981cited by this paper
• Plasminogen activator in the rodent brain.

  1981cited by this paper
• Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits

  1981cited by this paper
• Immunochemical characterization of human plasminogen activators.

  1981cited by this paper
• Dissolution Of Thrombi By Tissue Plasminogen Activator, Urokinase And Streptokinase In An Artificial Circulating System

  1981cited by this paper
• Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.

  1981cited by this paper
• Comparison of the Relative Fibrinogenolytic, Fibrinolytic and Thrombolytic Properties of Tissue Plasminogen Activator and Urokinase in Vitro

  1981cited by this paper
• Abnormal fibrinolysis in retinal vein occlusion.

  1981cited by this paper
• Immunological characterization of plasminogen activator activities in human tissues and body fluids.

  1981cited by this paper
• Comparison between the plasminogen activator activity in walls of superficial, muscle and deep veins.

  1981cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper
• Immunological identification and comparison of plasminogen activator forms in cultured normal human endothelial cells and smooth muscle cells.

  1981cited by this paper
• Generation of fibrinolytic activity by infusion of activated protein C into dogs.

  1981cited by this paper
• Plasminogen activator secretion by granule neurons in cultures of developing cerebellum.

  1981cited by this paper
• Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human uterine fluid.

  1981cited by this paper
• Haemostatic studies on retinal vein occlusion. Fibrinolytic response to venostasis as a prognostic factor for spontaneous recanalization.

  1981cited by this paper
• Studies on plasminogen activator and other proteases in subcultured human vascular cells.

  1981cited by this paper
• Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator?

  1981cited by this paper
• Neutralization of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Plasma: No Evidence for a Specific Inhibitor

  1981cited by this paper
• Studies on the Specific Fibrinolytic Effect of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Blood and in Various Animal Species in Vitro

  1981cited by this paper
• Comparative Studies on Human Activators of Plasminogen

  1981cited by this paper
• Purification and properties of a tissue plasminogen activator from hog kidney.

  1981cited by this paper
• Plasminogen activator: analysis of enzyme induction by ultraviolet irradiation mapping

  1981cited by this paper
• Purification and characterization of human vascular plasminogen activator.

  1980cited by this paper
• Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates.

  1980cited by this paper
• On the Regulation and Control of Fibrinolysis

  1980cited by this paper
• Molecular species of plasminogen activators secreted by normal and neoplastic human cells.

  1980cited by this paper
• Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.

  1980cited by this paper
• The effect of the anabolic steroid stanozolol on tissue plasminogen activator activity and plasmin inhibition in the rat

  1980cited by this paper
• Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man.

  1980cited by this paper
• Relationship between tissue plasminogen activator and the activators in blood and vascular wall.

  1980cited by this paper
• Plasminogen activator response after DDAVP: a clinico-pharmacological study.

  1980cited by this paper
• Separation of Plasminogen Activators from Human Uterine Tissue and a Comparison with Activators from Human Urine and Porcine Tissue

  1979cited by this paper
• Separation of Plasminogen Activators from Human Plasma and a Comparison with Activators from Human Uterine Tissue and Urine

  1979cited by this paper
• Immunological characterization of multiple weight forms of human cell plasminogen activators.

  1979cited by this paper
• Studies on the Fibrinolytic System in Human Plasma: Quantitative Determination of Plasminogen Activators and Proactivators

  1979cited by this paper
• Familial vascular plasminogen activator deficiency: a cause of cerebrovascular thrombosis.

  1979cited by this paper
• Purification and partial characterization of plasminogen activator from human uterine tissue.

  1979cited by this paper
• Interfering Factors in the Assay of Plasminogen Activators by the Fibrin Plate Method

  1979cited by this paper
• Effect of thrombin on plasminogen activator release from isolated perfused dog leg.

  1979cited by this paper
• Occurrence of both urokinase and tissue plasminogen activator in human seminal plasma.

  1979cited by this paper

• Postoperative Adhesions: Current Research on Mechanisms, Therapeutics and Preventative Measures

  2024cites this paper
• The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

  2023cites this paper
• Site-specific PEGylation of recombinant tissue-type plasminogen activator.

  2023cites this paper
• Toward 50 years of Seminars in Thrombosis and Hemostasis.

  2022cites this paper
• [Biochemical markers of thrombotic complications in the acute period of ischemic stroke].

  2022cites this paper
• Major Classes of Biotherapeutics

  2020cites this paper
• Changes in the content of some components of the plasminogen activation system in the plasma of bladder cancer patients

  2020cites this paper
• Crotoxin, a neurotoxin from Crotalus durissus terrificus snake venom, as a potential tool against thrombosis development.

  2019cites this paper
• Translational initiatives in thrombolytic therapy

  2017cites this paper
• The fibrinolytic system Recent advances

  2013cites this paper
• Thrombolytic Therapy in the Treatment of Stroke

  2012cites this paper
• fibrins: its significance in hemostatic defect in factor XIII deficiency Differential binding of plasminogen to crosslinked and noncrosslinked

  2011cites this paper
• 3 – Mechanisms of Thrombosis and Thrombolysis

  2011cites this paper
• UNIVERSIDAD DE ALCALÁ DEPARTAMENTO DE MEDICINA UNIDAD I + D ASOCIADA AL CNB-CSIC ANÁLISIS DE LA RESPUESTA INMUNITARIA INFLAMATORIA EN LA INFECCIÓN POR EL VIRUS DENGUE Y SU SIGNIFICANCIA CLÍNICA

  2011cites this paper
• The role of plasminogen-plasmin system in cancer.

  2009cites this paper
• Condicionantes epidemiológicos de salud y su relación con rendimiento escolar en el primer año de la carrera de medicina

  2009cites this paper
• Las proteasas en la progresión neoplásica

  2009cites this paper
• [Proteases in cancer progression].

  2009cites this paper
• Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals.

  2009cites this paper
• Fibrinolysis: the key to new pathogenetic mechanisms.

  2008cites this paper
• Immunopathogenesis of dengue hemorrhagic fever

  2008cites this paper
• Effects of heat and β-lactoglobulin on distribution of fluorescently labeled tissue-and urokinase-type plasminogen activators in a model milk system

  2007cites this paper
• The Plasminogen Activator System and Cancer

  2007cites this paper
• Cáncer de glándula mamaria y metástasis: Un creciente problema de salud pública en México

  2007cites this paper
• Rehabilitation of a hemophiliac with implants: a medical perspective and case report.

  2005cites this paper
• Mechanisms of Thrombolysis

  2005cites this paper
• Effect on Intracerebral Hemorrhage

  2005cites this paper
• Plasminogen activators and plasminogen activator inhibitors in endometriosis.

  2005cites this paper
• Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses

  2004cites this paper
• Mechanisms of Thrombosis and thrombolysis

  2004cites this paper
• Binding and fate of plasminogen activator inhibitor type-2 in breast carcinoma cells: rationale for development as a delivery vehicle of cytotoxins for anti-urokinase therapeutic strategies

  2004cites this paper
• Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon

  2004cites this paper
• Thrombolysis: From the Experimental Findings to the Clinical Practice

  2003cites this paper
• Tissue plasminogen activator induced by dengue virus infection of human endothelial cells

  2003cites this paper
• Molecular and Cellular Hemostasis and Fibrinolysis

  2002cites this paper
• Die Ergebnisse der intraarteriellen rt-PA-Lyse verschlossener femorodistaler Bypässe

  2002cites this paper
• Immunopathogenesis of Dengue Virus Infection

  2001cites this paper
• Immunopathogenesis of dengue virus infection.

  2001cites this paper
• Activation of coagulation and fibrinolysis during dengue virus infection

  2001cites this paper
• Tissue-type Plasminogen Activator (tPA)

  2001cites this paper
• Tissue-Type Plasminogen Activator (tPA)

  2001cites this paper
• La proteÛlisis en la invasiÛn y metÆstasis de la cØlula tumoral

  2000cites this paper
• La proteólisis en la invasión y metástasis de la célula tumoral

  2000cites this paper
• A mechanism for glu-plasminogen binding: an important aspect of the plasminogen activation cascade

  2000cites this paper
• Acquired Defects of Fibrinolysis Associated with Thrombosis

  1999cites this paper
• Hereditary Defects in Fibrinolysis Associated with Thrombosis

  1999cites this paper
• Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents.

  1999cites this paper
• Genetic polymorphism of murine tissue plasminogen activator associated with antiphospholipid syndrome

  1999cites this paper
• Coagulation and fibrinolytic activity in rats with naturally occurring gingivitis.

  1999cites this paper
• Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).

  1998cites this paper
• Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system.

  1998cites this paper
• Current concepts of coagulation and fibrinolysis.

  1998cites this paper
• Interventional use of plasminogen activators in central nervous system diseases.

  1998cites this paper
• Peritoneal Fibrinolysis and Adhesion Formation

  1997cites this paper
• Thrombolytic therapy in the treatment of stroke.

  1997cites this paper
• Plasminogen Activation by Invasive Human Pathogens

  1997cites this paper
• Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke

  1997cites this paper
• Ultrasensitive Fluorogenic Substrates for Serine Proteases

  1997cites this paper
• Analysis of tissue plasminogen activator specificity using peptidyl fluorogenic substrates.

  1997cites this paper
• Analysis of site-specific N-glycosylation of recombinant Desmodus rotundus salivary plasminogen activator rDSPA alpha 1 expressed in Chinese hamster ovary cells.

  1997cites this paper
• Regulation of plasminogen activator inhibitor activity in endothelial cells by tissue-type plasminogen activator*

  1996cites this paper
• Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women

  1996cites this paper
• Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension.

  1996cites this paper
• Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries.

  1996cites this paper
• Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

  1996cites this paper
• The Fibrinolytic System in Neoplasia

  1996cites this paper
• Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model.

  1996cites this paper
• Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism.

  1996cites this paper
• Inflammatory reactions at the blood-endothelial interface in acute stroke.

  1996cites this paper
• Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

  1996cites this paper
• Effects of insulin and some vasoconstrictors on the synthesis and release of t-PA and PAI-1 from cultured human umbilical vein endothelial cells

  1995cites this paper
• The Role of Fibrinolysis in the Pathogenesis of the Haemorrhagic Syndrome Produced by Virulent Isolates of African Swine Fever Virus

  1995cites this paper
• A Comparison of Cultured Cells with Other Promoters of Tissue Plasminogen Activator Kinetics

  1995cites this paper
• Carbazochrome sodium sulphonate (AC‐17) decreases the accumulation of tissue‐type plasminogen activator in culture medium of human umbilical vein endothelial cells

  1995cites this paper
• Cellular receptors for the plasminogen activators.

  1994cites this paper
• Peptide and Protein Drugs

  1994cites this paper
• Calcium signalling in platelets and other nonexcitable cells.

  1994cites this paper
• Global fibrinolytic capacity assessed by the serum D-dimer test. Correlation between basal and stimulated values.

  1994cites this paper
• Plasminogen-plasmin System in Tumor Invasion

  1994cites this paper
• Antithrombogenicity of lumbrokinase-immobilized polyurethane.

  1994cites this paper
• Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis.

  1994cites this paper
• Receptor-Mediated Endocytosis of Plasminogen Activators

  1994cites this paper
• Baseline plasma fibrinolysis anditscorrelation withclinical manifestations inpatients with Raynaud's phenomenon

  1993cites this paper
• Mechanisms of hemostasis. Effect on intracerebral hemorrhage.

  1993cites this paper
• Impaired fibrinolysis in patients with Blackfoot disease.

  1993cites this paper
• Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.

  1993cites this paper
• Pretreatment plasma levels of fibrinopeptide‐A (FPA), D‐dimer (DD), and von Willebrand Factor (vWF) in patients with operable cervical cancer: Influence of surgical‐pathological stage, tumor size, histologic type, and lymph node status

  1993cites this paper
• Factors Contributing to Increased Vascular Fibrinolytic Activity in Mongrel Dogs

  1993cites this paper
• Tissue plasminogen activator for thrombolytic therapy: expectation versus reality.

  1992cites this paper
• Pharmacokinetics of Peptides and Proteins: Opportunities and Challenges

  1992cites this paper
• The binding of plasminogen fragments to cultured human umbilical vein endothelial cells.

  1992cites this paper
• Mechanisms of fibrinolysis and clinical use of thrombolytic agents.

  1992cites this paper
• Tissue Plasminogen Activator for Thrombolytic Therapy: Expectation versus Reality

  1992cites this paper
• Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

  1992cites this paper
• The plasminogen-plasmin system in malignancy

  1992cites this paper
• Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells.

  1992cites this paper
• Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.

  1992cites this paper
• Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

  1992cites this paper
• Mechanisms of Tissue‐type Plasminogn Activator (tPA) Clearance by the Liver a

  1992cites this paper
• Mechanisms of Haemostasis

  1992cites this paper